Mavissakalian 1986b

Methods	ALLOCATION CONCEALMENT: adequate BLINDING: at least one measure was assessed by an independent assessor blind to treatment allocation
Participants	DIAGNOSIS: DSM‐III agoraphobia with panic AGE: mean=36.5 years SEX: 84% women HISTORY: mean duration of illness=10.5 years PSYCHIATRIC COMORBIDITY: Primary affective disorder or concurrent major depressive episode, schizophrenia, organic brain syndrome, OCD, somatization disorder, substance abuse, or severe personality disorder were excluded. MEDICAL COMORBIDITY: Physical illness precluding imipramine was excluded.
Interventions	ACUTE PHASE: 12 weeks 1. imipramine (mean=130 mg/d) + programmed practice (self‐directed in vivo graded exposure) + flooding twelve 90‐min group sessions (twelve 90‐min group sessions) 2. placebo + programmed practice + flooding ACUTE PHASE CO‐INTERVENTION: not specified MAINTENANCE: ‐ MODE OF DISCONTINUATION: naturalistic FOLLOW‐UP: at 6 months and 12 months after acute phase treatment. 63% and 55% were successfully followed up, respectively. INTERVENTIONS AFTER TRIAL DISCONTINUATION: 30% had interim treatment (individual therapy, group therapy, anxiolytics, antidepressants)
Outcomes	RESPONSE: >=50% reduction in self‐rated severity of phobia (imputed from mean & SD) REMISSION: High end‐state functioning GLOBAL: SElf‐rated Severity of Phobia [0‐8] PANIC ATTACK: Self‐rated Panic Overall Severity [0‐8] AGORAPHOBIA: FQ‐Ag [0‐40], Individualized phobic anxiety‐avoidance [0‐8], Behavioral avoidance‐anxiety index [0‐8] GENERAL ANXIETY: Zung Anxiety Scale [20‐80] DEPRESSION: Beck Depression Inventory [0‐63] FUNCTIONING: Clinician's Global Assessment [1‐5]
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate